Current Month 2008
Article Features
  Drug for Anemic Cancer Patients Raises Risk of Death
Breast Cancer Subtypes Linked to Survival from Secondary Brain Tumors
Cardiac Effects Associated with Breast Cancer Treatment Appear Lower with Dose-Dense Chemotherapy
Anti-Inflammatory Drugs Like Aspirin Could Reduce Breast Cancer Risk
Researchers Validate New Model for Breast Cancer Risk Assessment in Multiple Ethnic Groups
Researchers Identify New Genetic Marker for Breast Cancer
Hormone Therapy Increases Frequency of Abnormal Mammograms
Overexpression of an Inflammatory Marker May Be Associated with an Increased Risk of Breast Cancer
No Additional Benefit Found for Personalized Intervention to Promote Regular Mammography Screening
When Couples Face a Cancer Diagnosis, Women Carry Larger Emotional Burden than Men
Anchoring Protein Variant Associated with Increased Breast Cancer Risk
New Test Improves Upon Traditional Sentinel Node Biopsy
Women Who Have Stopped Estrogen Plus Progestin Therapy May Be At Increased Risk of Cancer
Breast Cancer Patients Suffer Considerable Wage Losses in First Year After Diagnosis


Women Who Have Stopped Estrogen Plus Progestin Therapy May Be At Increased Risk of Cancer

A follow-up study of women who stopped taking the hormone therapy of estrogen plus progestin after this intervention was discontinued as part of a clinical trial indicates that these women may have an increased risk of cancer, compared to women in the placebo group, according to a study in the Journal of the American Medical Association.

Cardiovascular disease and fracture risks were similar between the two groups, but women who took hormone therapy had an overall higher global risk index reflecting the balance of risks and benefits from a number of endpoints combined, including deaths.

The Women's Health Initiative (WHI) trial of estrogen plus progestin, which included 16,608 postmenopausal women, assessed whether conjugated equine estrogens (CEE) plus medroxyprogesterone acetate (MPA) prevents heart disease and hip fractures and increases the risk of breast cancer. The trial was stopped in 2002 when data indicated an increased risk of breast cancer and a failure to demonstrate an overall health benefit of the therapy. Further analysis showed that women in the CEE plus MPA group had higher risks of cardiovascular disease (CVD), coronary heart disease (CHD), stroke and venous thromboembolism and lower risks of fracture and colorectal cancer.

Read More of the Main Article

 
Visit the Ezine


Visit the BreastCenter

Visit the Quality Corner
Avon Breast Cancer Crusade - AVON the company for women

  This website is supported in part by an unrestricted educational grant provided by Avon